RxDoctor Payments Data

Lakisha Highe

Public Health & General Preventive Medicine · Charlotte, NCNPI 1275249971

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,314, 3.3 times the $1,006 reported in 2023.

$6,939in general payments, 2019–2025

Across 272 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • AstraZeneca$726
  • Novartis$641
  • UCB, Inc.$635
  • Johnson & Johnson$362
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,920100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few public health & general preventive medicine providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$18,041
Medicare patients
80
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxychloroquine Sulfate65$3,365
MethotrexateMethotrexate Sodium162$2,980
Leflunomide35$2,910
Celecoxib38$2,055
Prednisone207$888
Duloxetine Hcl26$362
Tizanidine Hcl13$271
Gabapentin13$258

Paid to pharmacies, not to this prescriber.

Other public health & general preventive medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →